The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care (special care & consumer healthcare) 15% In 2022, ...

In 2023, Chiesi group's revenue exceeded 3 billion euros ($3.24 billion), representing a 10 percent increase from 2022, with ...

A Massachusetts pharma company just got absorbed by a European giant — and the drug at the center of it all treats a deadly disease.

ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing ...

Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy Planned ...

-Transaction expected to close in the first half of 2023 About Amryt Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative ...

Early this month, medtech giant Baxter International revealed its plan to spin off its largest unit, kidney care, and indicated it was likely to do the same with some of its other business sectors. In ...

Chiesi is working with the BBC to show off its climate-conscious credentials, partnering with the British broadcaster on a web series episode about redesigning inhalers to reduce their environmental ...

Danielle Chiesi, a former hedge fund trader and key defendant in the sprawling Galleon Group insider trading case, was sentenced Wednesday to 2-1/2 years in prison, and the presiding judge gave a ...

Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is ...